Skip to main content

Advances in Pathogenesis and Therapies of Gout

156kviews
Editorial01 April 2022
Editorial: Advances in Pathogenesis and Therapies of Gout

Gout is one of the most common metabolic disorders in human caused by inflammatory responses to the deposition of monosodium urate (MSU) crystals , which form in the presence of increased urate concentrations. The pathogenesis of gout is that MSU crystal triggers strong inflammatory response by activating macrophages in tissues and promoting the collection of neutrophils to tissues or organs [1]. It has been reported that many soluble mediators are implicated in the initiation and amplification of the gout flare, including pro-inflammatory cytokines, lipid mediators and complement [2]. However, activation of the NOD-, LRR-and pyrin domain-containing protein 3 (NLRP3) inflammasome by monosodium urate crystals with release of IL-1β plays a major role in the initiation of the gout flare [3]. Interestingly, the gout flare is a self-limiting inflammation, and several mechanisms of resolution have been proposed, such as neutrophil extracellular traps [4], negative regulators of inflammasome and TLR signaling, and anti-inflammatory cytokines [5].It is noteworthy that gout is closely related to many comorbidities [6], especially cardiovascular diseases. To further our understanding of inflammatory regulation in the molecular pathophysiology of gout and to explore potential therapeutic approaches , this special issue exhibits a number of original research articles and review papers on the topic of advances in pathogenesis and therapies of gout. Galectin-9 (Gal-9) is a modulator of innate and adaptive immunity with both proand anti-inflammatory functions, dependent upon its expression and cellular location [11]. Using mouse models of gout, Mansour et al investigated the action of exogenous Gal-9 in MSU-gouty inflammation, which provide a new therapeutic strategy for preventing tissue damage in gouty arthritic inflammation. Elsaid et al examined the anti-inflammatory mechanism of proteoglycan 4(rhPRG4) in MSU stimulated monocytes by animal model, Their work indicates that rhPRG4 exerts an anti-inflammatory activity in gout PBMCs, mediated by its ability to reduce urate crystal phagocytosis. Si-Miao-San (SMS)is a traditional Chinese medicine that has been reported to relieve the symptoms of gouty arthritis [12]. A research by Cao et al explored the anti-inflammatory mechanism of SMS on gout through animal and cellular experiments.Uric acid is excreted mainly through the kidneys and intestines.A mini review by Yin et al summarized the effects of intestinal uric acid transporters and intestinal flora on uric acid excretion.Collectively, the original research and review articles in this special issue cover a series of important aspects in the field of inflammatory regulation and clinical management in gout which may provide new insights into the diagnosis and treatment of gout and hyperuricemia.

7,286 views

15 citations

Prevalence of Hyperuricemia Among Chinese Adults: Findings From Two Nationally Representative Cross-Sectional Surveys in 2015–16 and 2018–19
ORIGINAL RESEARCH
7 February 2022
Prevalence of Hyperuricemia Among Chinese Adults: Findings From Two Nationally Representative Cross-Sectional Surveys in 2015–16 and 2018–19
Mei Zhang, 12 more and Limin Wang
Objective: To determine the nationwide prevalence of hyperuricemia in China and evaluate its trends and associated risk factors. Methods: Using a multi-stage, stratified, cluster-randomized sampling design, two cross-sectional surveys (representative of national and provincial information) were conducted in 31 provinces (autonomous regions and municipalities) in mainland China, with 166,861 Chinese adults in 2015–16 and 168,351 in 2018–19. Serum uric acid (SUA) levels of all participants were measured after a >10-hour overnight fast. Hyperuricemia (HUA) was defined when SUA was >420 μmol/L. Prevalence estimates were weighted to represent the total population considering the complex sampling design. Multivariable logistic regression models was used to estimate factors associated with HUA. Results: The overall hyperuricemia prevalence in the Chinese adult population was 11.1% (95% confidence interval 10.3% to 11.8%) in 2015–16 and 14.0% (13.1% to 14.8%) in 2018–19; an alarming rise was observed in the three years. Hyperuricemia was more common in men with 19.3% (17.9% to 20.7%) in 2015–16 and 24.4% (23.0% to 25.8%) in 2018–19, although the prevalence also escalated from 2.8% (2.5% to 3.0%) in 2015–16 to 3.6% (3.2% to 4.0%) in 2018–19 in women. The hyperuricemia risk factors include the urban culture, settlement in the East, Zhuang descent, high education, heavy or frequent beer drinking, high red meat intake, physical inactivity, high body mass index, central obesity, hypertension, hyperlipidemia, and low glomerular filtration rate. Conclusion: The estimated hyperuricemia prevalence among Chinese adults was 14.0% in 2018-19; significant escalating trends were observed between 2015-16 and 2018-19.

23,858 views

419 citations

33,670 views

171 citations

ORIGINAL RESEARCH
5 January 2022
The Anti-Inflammatory and Uric Acid Lowering Effects of Si-Miao-San on Gout
Ling Cao, 11 more and Xiaoxia Zhu

13,389 views

48 citations

ORIGINAL RESEARCH
21 December 2021
Recombinant Human Proteoglycan 4 Regulates Phagocytic Activation of Monocytes and Reduces IL-1β Secretion by Urate Crystal Stimulated Gout PBMCs
Sandy ElSayed, 4 more and Khaled A. Elsaid

5,022 views

19 citations

ORIGINAL RESEARCH
15 July 2021
Gout Augments the Risk of Cardiovascular Disease in Patients With Psoriasis: A Population-Based Cohort Study
Zhiyong Chen, 5 more and James Cheng-Chung Wei

4,114 views

15 citations